title: Concurrent cisplatin-based chemoradiation for cervical carcinoma: tumor response, toxicity, and serum cytokine profiles.
abstract: OBJECTIVE
  To evaluate the relation between tumor response, treatment toxicity, and serum cytokine profiles in patients with cervical cancer receiving cisplatin-based chemoradiation.
  
  
  METHODS
  Forty-two patients with cervical carcinoma receiving chemoradiation were recruited. Hemogram, biochemistry profile, cytokine levels, tumor size, and toxicity were assessed weekly.
  
  
  RESULTS
  The absolute neutrophil count decreased accompanied by an increase in serum levels of G-CSF during chemoradiation. The sudden elevation of serum TGF-beta 1 and VEGF levels after the first fraction of brachytherapy accompanied with the development of greater radiation therapy (RT) morbidity. Lower pretreatment TGF-beta 1 and VEGF levels are associated with tumor response to chemoradiation.
  
  
  CONCLUSIONS
  The serial changes in serum cytokines during chemoradiation may correlate with tumor regression and treatment morbidity.
authors.affiliation: Department of Gynecology and Obstetrics, Mackay Memorial Hospital, Taipei, Taiwan.
authors.forename: Yuh-Cheng
authors.initials: YC
authors.lastname: Yang
authors.forename: Kung-Liahng
authors.initials: KL
authors.lastname: Wang
authors.forename: Tsung-Hsien
authors.initials: TH
authors.lastname: Su
authors.forename: Hui-Fen
authors.initials: HF
authors.lastname: Liao
authors.forename: Meng-Hao
authors.initials: MH
authors.lastname: Wu
authors.forename: Tze-Chien
authors.initials: TC
authors.lastname: Chen
authors.forename: Ming-Chao
authors.initials: MC
authors.lastname: Huang
authors.forename: Yu-Jen
authors.initials: YJ
authors.lastname: Chen
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000097:blood; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000528:radiation effects; D011878:Radiotherapy; D016212:Transforming Growth Factor beta / Q000097:blood; D053773:Transforming Growth Factor beta1; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D016207:Cytokines; D015850:Interleukin-6; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D042461:Vascular Endothelial Growth Factor A; D016179:Granulocyte Colony-Stimulating Factor; D002945:Cisplatin